Loading
A phase 2 trial of Samarium-153 lexidronam in Osteosarcoma, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, recorded as terminated on the registry.
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma is a phase 2 interventional study registered as NCT01886105 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with 4 participants recorded, started 2013-08-19 and due to reach its primary completion in 2015-12-11. Interventions recorded: Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy. Conditions recorded: Metastatic Osteosarcoma.
Linked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
4 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2019-10-29), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Treated Participants With 6-month Progression Free Survivalprimary | SmEDTMP/Autologous Stem Cell Infusion/RT | 4 | 0 participants | - | - | link |
Shares Samarium-153 lexidronam and the tag pipeline.
Shares Samarium-153 lexidronam and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.